Cleveland-Cliffs enters the final stretch before its October 19 earnings print with shorts trimming positions yet options markets turning more defensive — a split that makes the current setup worth watching closely.
The most striking shift this week is in short positioning, and it tells a story of gradual retreat. At 12% of free float, short interest remains firmly in elevated territory. But the trend is clearly moving the other direction. Shorts shed roughly 4.1% of their position over the past week and are down nearly 7% from a month ago — the clearest sustained unwind since the late-August peak near 83.7 million shares. The lending market is not adding pressure to that unwind: availability is deep at around 742% of short interest, meaning shares to borrow are plentiful relative to what's already been lent out. Cost to borrow, while doubling over the past week to 0.37%, remains essentially trivial in absolute terms for a stock trading near $11.79. The mechanics simply don't support a squeeze narrative here.
Options are telling a different story. Demand for downside protection has climbed to its most elevated point in roughly a month. The put/call ratio hit 0.54 — almost 1.7 standard deviations above its 20-day average of 0.48 — the highest reading in this window. The full-year range sits between 0.28 and 0.61, so the current reading is not extreme, but the drift upward has been consistent since late August. That shift tracks the stock's own trajectory: CLF is down 4.1% on the week and has barely moved over the past month, even as the July earnings print delivered a stunning 26% single-day gain. Peers have had a rough week too — dropped 7.9% and fell nearly 7% — suggesting sector-wide pressure rather than CLF-specific weakness. held up better, up nearly 1% on the week, pointing to some divergence within the group.
The Street is cautiously constructive but far from unified. JP Morgan's Bennett Moore raised his target from $11 to $13 while holding a Neutral rating on September 9, the most recent action from a major bank. That came after a cluster of upgrades following the July blowout quarter, when GLJ Research moved to Buy and Wells Fargo and Barclays both lifted targets post-earnings. The mean analyst target now sits at $12.30, slightly above the current price, giving limited implied upside on consensus. Barclays remains the clear bear, with an Underweight and a $10 target. Valuation multiples have been compressing: the P/E has fallen more than 20 points over 30 days, and EV/EBITDA has eased 0.58x in the same window, suggesting the market is trimming the premium earned after the Q2 beat. The ORTEX EPS surprise factor ranks in the 76th percentile — historically a beat-and-raise name — but the short score of 55 ranks in just the 8th percentile relative to the broader universe, signaling that short positioning remains a meaningful overhang by any cross-sectional measure.
The one genuinely notable institutional footnote is Slate Path Capital, which added over 9 million shares in Q2 to reach nearly 5% of outstanding shares. That is a material conviction move by an active manager, though the position predates the July earnings surge and the subsequent drift lower. No activist 13D filings are on record — the 13D/G register carries only passive index and quasi-index holders, with State Street trimming its stake from 6.9% to 5.8% in its most recent filing. The CFO's open-market sale of $2.9 million worth of stock in early June — executed without a 10b5-1 plan — is the most recent insider signal, though it came before the Q2 print that sent shares sharply higher, reducing its interpretive weight now.
The October 19 print is the next hard catalyst. After the last quarter's 26% one-day move, the bar for surprise is higher and the options market is starting to price that asymmetry. Watch whether the put/call ratio continues its climb into mid-October and whether short covering accelerates — or stalls — as the report approaches.
See the live data behind this article on ORTEX.
Open CLF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
